Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$27.31 USD
+2.29 (9.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.24 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELVN 27.31 +2.29(9.15%)
Will ELVN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Commit To Purchase Enliven Therapeutics At $17.50, Earn 19.7% Annualized Using Options
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Recommendation for Enliven Therapeutics Based on CML Treatment Market Dynamics and Patient Switching Trends
Analysts Are Bullish on These Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Enliven Therapeutics (ELVN)
Enliven initiated with bullish view at Baird, here's why